Nurtec™ ODT (rimegepant) orally disintegrating tablets 75 mg

You are cordially invited to attend a

Nurtec™ ODT (rimegepant) virtual speaker program sponsored by Biohaven Pharmaceuticals

What Do You Expect From Acute Treatments for Migraine?

Program Objectives

- Explore how a single dose of Nurtec ODT (orally disintegrating tablet) can:
  - Provide some patients with rapid and sustained relief from their migraine in just 1 dose
  - Enable many patients to quickly return to and maintain their normal function
  - Address the current unmet needs for the acute treatment of migraine

INDICATION

Nurtec™ ODT (rimegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.

Program Details

Wednesday, September 16, 2020

6:30 PM CT

https://zoom.us/join

Meeting ID: 93350247571

Registration Information

Please register by going to: **https://www.scimedregister.com**

Please reference invitation code: RWL6GH

Speaker Information

Jaclyn R. Duvall, MD
Neurologist, Headache Specialist
Utica Park Clinic Headache Center
Tulsa, OK

Neuroscience Sales Specialist

Todd Reichert

+1 918.691.1998

todd.reichert@biohavenpharma.com

Biohaven Pharmaceuticals is required to disclose all items of value provided to healthcare providers and to disclose these amounts publicly. By attending this virtual speaker program, you are accepting the disclosure of the cost of the meal.

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding:* It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please see accompanying full Prescribing Information provided with this invitation.

© 2020 Biohaven Pharmaceuticals, Inc.

biohaven™ pharmaceuticals

US-RIMODT-2000240 03/20